Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.35 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7342501 | 0.95 | AGTR1 (0.41) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL8188390 | 0.94 | AGTR1 (0.38) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL7333131 | 0.92 | BRS3 (0.39) | BRS3ALDH1A1AGTR1AGTR2 | |
| SCHEMBL7334514 | 0.88 | AGTR1 (0.41) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL7362349 | 0.87 | ALDH1A1 (0.35) | BRS3ALDH1A1AGTR1AGTR2LTB4R2 | |
| SCHEMBL7332613 | 0.87 | KDM4E (0.40) | AGTR1AGTR2HCRTR2 | |
| SCHEMBL7333245 | 0.87 | AGTR1 (0.43) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL8177702 | 0.87 | AGTR1 (0.39) | BRS3AGTR1AGTR2LTB4R2 | |
| SCHEMBL7333254 | 0.87 | LTB4R2 (0.37) | BRS3ALDH1A1AGTR1AGTR2LTB4R2 | |
| SCHEMBL9552249 | 0.86 | BRS3 (0.49) | BRS3AGTR1AGTR2LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6090828-A | ARTHERIOSCLEROSIS | REITZ DAVID B (US) | 2000-07-18 | — | — | US | disclosed |
| US-5451593-A | Method of using 5-arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of a glaucoma disorder | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5451591-A | Method of using 5-arylheteroarylalkyl-1,3 5-trisubstituted-1,24-triazole compounds for treatment of circulatory disorders | G. D. SEARLE & CO. (US) | 1995-09-19 | — | — | US | disclosed |
| US-5196537-A | Angiotensin/II/ antagonists; hypotensive agents | G. D. SEARLE & CO. (US) | 1993-03-23 | — | — | US | disclosed |
| EP-0504888-A1 | 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders | G.D. Searle & Co. (US) | 1992-09-23 | — | — | EP | disclosed |